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METHOD OF INHIBITING AB-TYPE 
BACTERIAL TOXINS AND TREATMENT FOR 
ASSOCIATED DISEASES 
RELATED APPLICATION 
This application claims priority from provisional applica-
tion Ser. No. 61/086,918, which was filed on 7 Aug. 2008 and 
which is incorporated herein by reference in its entirety. 
STATEMENT OF GOVERNMENT RIGHTS 
The invention claimed herein was made with at least partial 
support from the U.S. Government through NIH grants ROI 
AI073783, K22 AI054568 and R03 AI067987 to K. Teter. 
Accordingly, the goverrnnent may have certain rights in the 
invention, as specified by law. 
FIELD OF THE INVENTION 
This invention relates to infectious diseases and, more 
specifically, to inhibitors ofbacterial toxins of the type having 
a catalytic A subunit and a cell-binding B subunit and, espe-
cially to those within this group which function as ADP-
ribosylating toxins. 
BACKGROUND OF THE INVENTION 
2 
Toxin Dislocation and Cellular Intoxication" provides proof-
of-principle for an anti-toxin therapeutic strategy that blocks 
the thermal unfolding of the toxin A chain. This paper was 
filed as part of the provisional application to which priority is 
5 claimed herein. As demonstrated in this experimental work, 
which is further expanded below, the inhibition of A chain 
unfolding prevents toxin passage into the cytosol and, hence, 
prevents productive intoxication. 
Also further detailed below are data from our study entitled 
10 "Hsp90 is Required for Transfer of the Cholera Toxin Al 
Subunit from the Endoplasmic Reticulum to the Cytosol." 
These data demonstrate that geldanamycin (GA), an inhibitor 
of heat shock protein 90 (Hsp90), blocks toxin passage into 
the cytosol, also blocking productive intoxication. This 
15 experimental work shows that (i) Hsp90 binds directly to the 
catalytic CTAl subunit with high affinity; (ii) GA blocks the 
binding of Hsp90 to CTAl; (iii) GA blocks CTAl passage 
from the endoplasmic reticulum (ER) to the cytosol; and (iv) 
GA blocks CT intoxication in cultured cells and in the physi-
20 ological ilea! loop model of toxin-induced diarrhea. We have 
found that GA is effective in blocking CT intoxication in 
cultured cells at a level of0.1 µM. 
We have also now shown that sodium 4-phenylbutyrate 
(PBA) blocks CT activity against cultured cells in a dose-
25 dependent manner. Additionally, we have shown that PBA 
blocks CTAl export to the cytosol. One of our collaborating 
laboratories has reported that PBA also blocks CT activity in 
the ilea! loop test system. As with ricin and exotoxin A, 
Bacterial toxins have been known to be primary mediators neither GA nor PBA have, so far, shown to inhibit Shiga toxin 
of a number of diseases both of the intestinal tract and of other 30 activity against cultured cells. 
Yet additionally, we have generated preliminary evidence 
that both GA and PBA will be effective against pertussis toxin 
(PT). We have shown that Hsp90 binds to the catalytic subunit 
of PT (PTS 1) in anATP-dependent manner that is inhibited by 
35 GA. We have also shown that PBA inhibits the thermal 
organ systems. Some bacterial toxins are known as AB-type 
toxins, since they are composed of a catalytic A subunit and a 
cell-binding B subunit. Examples of such AB-type toxins 
include cholera toxin (CT), the E. coli heat-labile toxin (LT) 
responsible for traveler's diarrhea, the B. pertussis toxin 
responsible for much of the symptomatology of whooping 
cough, exotoxin-A produced by Pseudomonas aeruginosa 
strains often found in the respiratory tract of cystic fibrosis 
patients or on the damaged skin of burn patients, Shiga toxin 
produced in the intestinal disease shigellosis, and the similar 40 
toxin produced by enterohemorrhagic E. coil and which has 
lately been associated in the U.S. with contaminated produce 
and ground beef products. 
Typically, the diseases caused by these bacterial toxins are 
treated symptomatically because drugs effective against the 45 
toxins themselves have not been available. Except in the case 
of pertussis, prior immunizations have either not been avail-
able or have not been very successful in conferring a protec-
tive immunity against these toxins. 
Accordingly, there is a great need for drugs that would act 50 
directly against these toxins, interfering with their mecha-
nisms of action so as to prevent entry of the active toxin into 
targeted host cells and cellular intoxication. The present 
invention provides such long-needed drugs and discloses a 
proposed new model mechanism by which extracellular AB- 55 
type toxins gain access to the affected cells of the body. 
SUMMARY OF THE INVENTION 
unfolding of PTSl. Intoxication assays with PT and GA or 
PBA remain to be completed. 
PBA is an FDA approved drug. The maximal FDA 
approved dose of PBA for therapeutic use is 20 g/d, which 
produces PBA serum levels between 600 and 1, 700 uM. This 
is from oral administration of four 500 mg tablets over the 
course of a day. We have shown that PBA is effective against 
CT intoxication of cultured cells at a concentration ranging 
from 10-100 µM. This concentration is well below the maxi-
mum permissible serum level of PBA. In addition, as noted 
above, a dose of 20 g/d produces serum levels of PBA 
between 600 and 1,700 uM, however, it is not necessary to 
deliver PBA to the serum, but only that it be present in the 
intestines, which is where it would be delivered by oral 
administration. Thus, an effective dose of PBA is deliverable 
to the intestinal epithelium with a drug concentration far 
below the maximal dosage. Two published papers that have 
reported PBA as a therapeutic "chemical chaperone" for 
treating genetic diseases are by A. F. Collins et al., "Oral 
sodium phynylbutyrate therapy in homozygous beta thalas-
semia: a clinical trial"; Blood, 1995, 85:43-49; and Jeffrey H. 
Teckman, "Lack of effect of oral 4-phenylbutyrate on seum 
alpha-1-antitrypsin in patients with a-1-antitrypsin defi-
ciency: a preliminary study"; J. Ped. Gastroenterology and 
With the foregoing in mind, the present invention advan-
tageously provides a new understanding of the mechanisms 
of action of AB-type bacterial toxins at the cellular level and 
identifies compounds which are able to block these toxins' 
biologic activity, consequently, the compounds are useful in 
methods of treatment of the respective diseases. 
60 Nutrition, July 2004, 39:34-37. These two papers report PBA 
serum levels between 600 and 1,700 uM. 
Our soon to be published paper titled "Stabilization of the 
Tertiary Structure of the Cholera Toxin Al Subunit Inhibits 
65 
BRIEF DESCRIPTION OF THE DRAWINGS 
Some of the features, advantages, and benefits of the 
present invention having been stated, others will become 
apparent as the description proceeds when taken in conjunc-
US 8,436,048 Bl 
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tion with the accompanying drawings, presented for solely 
for exemplary purposes and not with intent to limit the inven-
tion thereto, and in which: 
FIG. 1 shows stability curves for the catalytic CTAl sub-
unit in the absence or presence of sodium 4-phenylbutyrate 5 
(PBA), as demonstrated by near-UV circulardichroism (CD), 
fluorescence spectroscopy, and far-UV CD (from left to right, 
respectively, in the figure); 
4 
CTAl from untreated (no treatment) or glycerol-treated 
(+glycerol) cells by SPR; CTA standards (10 ng/ml and 1 
ng/ml) were perfused over the sensor slide as positive con-
FIG. 2 demonstrates lowered CT toxicity to cells in culture 
when the cells are treated with geldanamycin (GA); 
FIG. 3 is a line graph showing the effect of PBA treatment 
on the cellular toxicity of up to 10 ng/ml CT; 
trols; cytosolic fractions from unintoxicated cells and cells 
intoxicated in the presence ofbrefeldin A ( +BfA) were also 
generated for this experiment; one of four representative 
experiments is shown; the arrow indicates when the sample 
was removed from the perfusion buffer; at the end of each 
experiment, bound sample was stripped from the sensor slide 
10 with a 5 min PBST wash at pH 6.0; 
FIG. 4 provides the same comparison as FIG. 3, except the 
CT concentration is extended up to 100 ng/ml; 
FIG. 5 is another line graph comparing the effect of no 15 
treatment (control), treatment with geldanamycin and treat-
ment with PBA on cell toxicity caused by exotoxin A (ETA) 
of Pseudomonas aeruginosa; 
FIG. 6 compares cell toxicity due to ricin when the cells are 
untreated (control), treated with geldanamycin and treated 20 
withPBA; 
FIG. 7 shows that glycerol prevents the temperature-in-
duced conversion ofCTAl to a protease-sensitive conforma-
tion: (a): 1 mg samples of the CTA1/CTA2 heterodimer were 
exposed to lOmM ~-ME for 5 minin the absence or presence 25 
of 10% glycerol before loading on a non-reducing SDS-
PAGE gel; 1 mg of a CTA1/CTA2 heterodimer that was not 
exposed to ~-ME was also run on the gel; samples were 
visualized by Coomassie staining, which does not detect the 
dissociated 5 kDa CTA2 subunit; (b ): samples of the reduced 30 
CTA1/CTA2 heterodimer were placed in 20 mM sodium 
phosphate buffer (pH 7.0) lacking or containing 10% glyc-
erol; after incubation at the stated temperatures for 1 hr, the 
samples were shifted to 4 ° C. and exposed to thermolysin for 
1 hr at 4° C.; samples were visualized by SDS-PAGE and 35 
Coomassie staining; 
FIG. 10 indicates that glycerol treatment stimulates CTAl 
secretion from intoxicated cells; HeLa cells pulse-labeled at 
4 ° C. for 30 min with 1 mg/ml of CT were chased for 2 hr at 
37° C. in toxin-free medium that lacked (no treatment) or 
contained 10% glycerol (+glycerol); media samples from 
these cells and from unintoxicated control cells were then 
analyzed by SPR with a sensor slide that had been coated with 
an anti-CTA antibody; CTA standards ( 10 ng/ml and 1 ng/ml) 
were also perfused over the sensor slide as positive controls; 
one of four representative experiments is shown, the arrow 
indicates when the sample was removed from the perfusion 
buffer; at the end of each experiment, bound sample was 
stripped from the sensor slide with a 5 min PBST wash at pH 
6.0; 
FIG. 11 depicts that CTAl secretion from intoxicated cells 
occurs in a time-dependent process that is inhibited by BfA; 
(a-b): HeLa cells pulse-labeled at 4° C. for 30 min with 1 
mg/ml of CT were chased for 30, 60, 90, or 120 min at 3 7° C. 
in toxin-free medium that lacked (a) or contained (b) 10% 
glycerol; media samples from these cells, from intoxicated 
cells chased for 120 min in the presence of 5 mg BfA/ml (120 
min+BfA), and from unintoxicated control cells were then 
analyzed by SPR with a sensor slide that had been coated with 
an anti-CTA antibody; CTA standards ( 10 ng/ml and 1 ng/ml) 
were also perfused over the sensor slide as positive controls; 
the arrow indicates when the sample was removed from the 
perfusion buffer; at the end of each experiment, bound sample 
was stripped from the sensor slide with a 5 min PBST wash at 
pH 6.0; (c): to approximate the amount of CTAl secreted 
from intoxicated cells, association rate constants were calcu-
lated from the SPR data obtained for the secreted pools of 
CTAl and forthe ten-fold serial dilutions of purified CTA that 
were perfused over the CTA sensor slide; the association rate 
constants for the CTA standards were plotted as a function of 
protein concentration (n=3; averages±standard deviations are 
shown); the slope of the resulting standard curve was then 
used to calculate the concentration of CTAl in untreated and 
glycerol-treated media samples; the means±standard errors 
of the means of five independent experiments are shown; 
CTA standards are presented as diamonds; untreated media 
samples are presented as an open square; and glycerol-treated 
media samples are presented as an open circle; 
FIG. 12 shows that glycerol does not inhibit the dissocia-
FIG. 8 shows thermal stabilization of CTAl by glycerol: 
(a-d): the temperature-induced unfolding of a purified, His6-
tagged CTAl protein in the absence (a-b) or presence (c-d) of 
10% glycerol was monitored by near-UV CD (a, c) and far- 40 
UV CD (b, d); both measurements were conducted near-
simultaneously on the same sample after equilibration at each 
temperature for 4 min; measurements were taken with a 
4-mm optical path-length rectangular quartz cuvette at a pro-
tein concentration of 73 mg/ml in 20 mM sodium borate 45 
buffer (pH 7.4) containing 150 mM NaCl; the change in color 
from blue to red corresponds to a change in temperature from 
18° C. to 65° C.; (e-f): depicts thermal unfolding profiles for 
CTA1-His6 in the absence (red) or presence (blue) of 10% 
glycerol were derived from the data presented in panels a-d; 50 
(e): for near-UV CD analysis, the mean residue molar ellip-
ticities at 280 nm ([8]280) were plotted as a function of 
temperature; (f): for far-UV CD analysis, the mean residue 
molar ellipticities at 220 nm ([8]220) were plotted as a func-
tion of temperature; 55 tion of CTAl from CTA2/CTB5; after appending CT to an 
SPR sensor slide, a baseline measurement corresponding to 
the mass of the holotoxin was recorded; reduced PDI was then 
perfused over the CT-coated sensor slide in the presence of 
10% glycerol; PDI was present in the perfusion buffer for the 
FIG. 9 illustrates that glycerol treatment blocks CTAl dis-
location from the ER; HeLa cells were pulse-labeled at 4 ° C. 
for 30 min with 1 mg/ml of CT; the cells were then chased for 
2 hr at 37° C. in toxin-free medium that either lacked or 
contained 10% glycerol; selective permeabilization of the 
plasma membrane with digitonin was used to partition cell 
extracts into separate membrane (pellet; P) and cytosolic 
(supernatant; S) fractions; (a): both fractions were probed by 
Western blot to establish the distributions of cytosolic marker 
Hsp90, ER marker PDI, and CTAl; one of two representative 
experiments is shown; (b ): a sensor slide coated with an 
anti-CTA antibody was used to detect the cytosolic pool of 
60 duration of the experiment; an anti-CTA antibody was also 
added to the perfusion buffer 420 sec into the experiment; 
FIG.13 indicates that glycerol treatment interferes with CT 
intoxication; CHO cells were incubated for 2 hrs with varying 
concentrations of CT in media lacking (circles) or containing 
65 (squares) 10% glycerol; cAMP levels were then assessed with 
the use of an [125I]-cAMP competition assay; results 
(means±SEMs of 4 independent experiments with triplicate 
US 8,436,048 Bl 
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samples) are expressed as percentages of the maximal CT 
response for all tested conditions; 
FIG. 14 presents data that glycerol inhibits CTAl degra-
dation by the 20S proteasome; (a): reduced CTA1/CTA2 het-
erodimers were incubated at 37° C. with 100 nM of the 20S 5 
proteasome in the absence or presence of 10% glycerol; 
samples taken at the indicated time points were visualized by 
SDS-PAGE and Coomassie staining; (b ): an identical proto-
col was followed with a-casein as the sample protein; 
6 
CTAl sensor slides; all the collected data are shown; the red 
lines represent best fit curves derived from the raw data using 
1 :2 (CTAl :Hsp90 orCTAl :GRP94) binding models; the SPR 
traces display, from the top to the bottom of the graph, results 
for decreasing concentrations of the ligand; 
FIG. 19 GA but not NECA inhibits CT intoxication; (a): 
CHO cells were incubated with varying concentrations of CT 
in the absence of additional treatment, in the presence of0.1 
mM GA, or in the presence of 0 .1 mM NECA; after two hours 
10 of continual toxin exposure, toxicity was assessed from the 
elevated levels of intracellular cAMP; the averages±standard 
errors of the means of at least four independent experiments 
with triplicate samples are shown; (b): CHO cells were incu-
bated for 4 hours with varying concentrations of ricin in the 
FIG. 15 shows how glycerol blocks the time-dependent 
appearance of CTAl in the cytosol; HeLa cells were pulse-
labeled at 4 ° C. for 30 min with 1 mg/ml of CT; the cells were 
then chased for 1, 2, 3, 4, or 5 hr at 37° C. in toxin-free 
medium that lacked or contained 10% glycerol; selective 
permeabilization of the plasma membrane with digitonin was 
used to partition cell extracts into separate membrane and 
cytosolic fractions; an SPR sensor slide coated with an anti-
CTA antibody was used to detect the cytosolic pools ofCTAl 
from untreated (green lines) or glycerol-treated (red lines); 
CTA standards (10 ng/ml, 1 ng/ml, and0.1 ng/ml; black lines) 20 
were perfused over the sensor slide as positive controls; a 
cytosolic fraction from unintoxicated cells (blue line) was 
also generated for this experiment; a small pool of CTAl was 
detected in the cytosol of untreated cells after 1 hr of chase; 
the amount of cytosolic CTAl increased after 2 hr of chase 
and remained constant over 3 and 4 hr of chase; after five 
hours of chase, an additional increase in cytosolic CTAl was 
detected; no cytosolic pool of CTAl was detected at any time 
point for the glycerol-treated cells; at the end of each experi-
ment, bound sample was stripped from the sensor slide with a 30 
PBST wash at pH 6.0; 
15 absence or presence of 0.1 mM NECA; toxicity was then 
determined from the incorporation of [35S]methionine into 
newly synthesized proteins; the averages±ranges of two inde-
pendent experiments with triplicate samples are shown; (c): 
mock/CT /CT +GA/GA/forskolin/forskolin +GA; 
FIG. 20 shows that GA also inhibited CT activity in the 
ilea! loop model of intoxication; surgically sealed sections of 
intestine were injected with 1 mg of CT in the absence or 
presence of GA; hours later, the CT-injected loop displayed 
the distended morphology indicative of water accumulation 
25 resulting from productive intoxication; in contrast, loops that 
were injected with both CT and 1 or 5 uM GA exhibited a 
minimal amount of fluid accumulation and intestinal disten-
sion; while GA derivatives have been evaluated by others as 
FIG. 16 shows CTAl secretion from Vero cells; Vero cells 
pulse-labeled at 4° C. for 30 min with 1 mg/ml of CT were 
chased for 2 hr at 37° C. in toxin-free medium that lacked (no 
treatment) or contained 10% glycerol (+glycerol); a separate 35 
set of intoxicated cells were chased in medium that contained 
either 5 mg/ml of BfA ( +BfA) or both 10% glycerol and 5 
mg/ml of BfA (+glycerol & BfA); media samples from the 
intoxicated cells and from unintoxicated control cells were 
then analyzed by SPR with a sensor slide that had been coated 40 
with an anti-CTA antibody; CTA standards (10 ng/ml and 1 
ng/ml) were also perfused over the sensor slide as positive 
controls; the arrow indicates when the sample was removed 
from the perfusion buffer; at the end of each experiment, 
bound sample was stripped from the sensor slide with a 5 min 45 
PBST wash at pH 6.0; 
FIG. 17 indicates that GA but not N-ethylcarboxamidoad-
enosine (NECA) inhibits the interaction between CTAl and 
Hsp90; either Hsp90 (a) or GRP94 (b) was perfused over a 
CTAl-coated SPR sensor slide under the following condi- 50 
tions: no ATP in the perfusion buffer, 1 mM ATP in the 
perfusion buffer, 1 mMATP and 0.1 mM GA in the perfusion 
buffer, or 1 mM ATP and 0.1 mM NECA in the perfusion 
buffer; Hsp90 and GRP94 were used at 100 mg/ml concen-
trations; arrowheads denote the time point at which the ligand 55 
was removed from the perfusion buffer; one of several repre-
sentative experiments is shown; in panel b, the * * * indicates 
all experimental conditions other than GRP94+ATP; 
FIG. 18 shows binding of CTAl to Hsp90 or GRP94; 
Hsp90 (a) or GRP94 (b) were perfused over a CTAl-coated 60 
SPR sensor slide at 100, 400, 800, 1,600, and 3,200 nM 
concentrations; (b ): GRP94 was perfused over a CTAl-
coated SPR sensor slide at concentrations of 100, 400, 800, 
and 1,600 nM; note that the results for Hsp90 and GRP94 are 
plotted on different scales; for all conditions, 1 mMATP was 65 
present in the perfusion buffer; measurements were per-
formed in three independent experiments with three different 
anti-cancer agents in phase I clinical trials, the protective 
effect of GA in a physiological model of intoxication is 
strongly suggestive that it could also be used as a therapeutic 
to prevent or treat cholera; 
FIG. 21 shows that 4-phenylbutyric acid (PBA) and 
geldanamycin (GA) prevent the catalytic subunit of cholera 
toxin (CTAl) from entering the cytosol of target cells; HeLa 
cells were pulse-labeled at 4 ° C. for 30 min with 1 mg/ml of 
CT; the cells were then chased for 2 hr at 37° C. in toxin-free 
medium or toxin-free medium that contained either PBA, 
GA, NECA, or brefeldinA (BfA); selective permeabilization 
of the plasma membrane with digitonin was used to partition 
cell extracts into separate membrane and cytosolic fractions; 
a surface plasmon resonance (SPR) sensor slide coated with 
an anti-CTA antibody was used to detect the cytosolic pools 
ofCTAl; CTA standards (1 ng/ml and 0.1 ng/ml) were per-
fused over the sensor slide as positive controls, and the cyto-
solic extract from unintoxicated cells was perfused over the 
slide as a negative control; an increase in the SPR response 
signal indicates ligand binding to the plate; these data dem-
onstrate that less CTAl was found in the cytosol of PBA- or 
GA-treated cells than in the cytosol of cells chased in the 
absence of drug treatment; NECA, a drug that inhibits GRP94 
but not Hsp90, did not inihbit the appearance of CTAl in the 
cytosol; BfA is a (toxic) drug known to inhibit toxin traffick-
ing to the ER, and, thus, toxin passage into the cytosol; at the 
end of each experiment, bound sample was stripped from the 
sensor slide with a PBST wash at pH 6.0; 
FIG. 22 shows how 4-phenylbutyric acid (PBA) inhibits 
cholera intoxication in a dose-dependent manner; CHO cells 
were incubated with varying concentrations of cholera toxin 
(CT) in the absence of additional treatment or in the presence 
of the indicated PBA concentrations; after 2 hours of con-
tinual toxin exposure, toxicity was assessed from the elevated 
levels of cAMP; 
FIG. 23 presents data showing the Hsp90 inhibitor 
geldanamycin (GA) blocks the interaction between Hsp90 
and the catalytic A subunit of pertussis toxin (PTS 1 ); surface 
plasmon resonance (SPR) was used to characterize the inter-
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are provided so that this disclosure will be thorough and 
complete, and will fully convey the scope of the invention to 
those skilled in the art. Other features and advantages of the 
invention will be apparent from the following detailed 
description, and from the claims. 
Our paper published in Journal of Molecular Biology, 
(2007) 3 7 4, 1114-1128 presents the first experimental data 
demonstrating that isolated cholera toxin Al polypeptide 
(CTAl) is a thermally unstable protein. CTAl is held in a 
action between Hsp90 and PTSl; an increase in the Micro 
Refractive Index Units (Micro RIU) is indicative of a physical 
interaction between two proteins; Hsp90 was perfused over 
an PTS I-coated SPR sensor slide under the following condi-
tions: no ATP in the buffer, ATP in the buffer, or both GA and 5 
ATP in the buffer; the binding ofHsp90 to client proteins is an 
ATP-dependent process; the lack of interaction between 
Hsp90 and PTS 1 in the absence of ATP or in the presence of 
GA demonstrates the specificity of the protein-protein inter-
action; 10 stable conformation by its association with CTA2/CTB5, but 
it can spontaneously unfold at physiological temperature 
when separated from the holotoxin in the endoplasmic reticu-
lum (ER). We have proposed a new model ofCTAl translo-
cation from the ER in that this spontaneous unfolding event 
FIG. 24 shows the thermal stabilization of the catalytic 
subunit of pertussis toxin (PTSl) by 4-phenylbutyric acid 
(PBA ); ( A-D): the temperature-induced unfolding of PTS 1 in 
the absence (A-B) or presence (C-D) of 0.1 mM PBA was 
monitored by far-UV CD (A, C) and near-UV CD (B, D); the 
change in color from blue to red corresponds to a change in 
temperature from 18° C. to 65° C.; (E-F): thermal unfolding 
profiles for PTSl in the absence (red) or presence (blue) of 
PBA were derived from the data presented in panels A-D; (E): 
for far-UV CD analysis, the mean residue molar ellipticities 
at 220 nm ([8]220) were plotted as a function of temperature; 
(F): for near-UV CD analysis, the mean residue molar ellip-
ticities at 280 nm ([8]280) were plotted as a function of 
temperature; and 
FIG. 25 resents data indicating that geldanamycin (GA) 
and 4-phenylbutyric acid (PBA) do not protect cultured cells 
against Shiga toxin; Vero cells expressing a destabilized vari-
ant of green fluorescent protein (tl/2=2 hr) were exposed to 
Ham's F-12 medium containing tenfold dilutions of culture 
supematants from Shiga toxin-producing E. coli 0157 strain 
RM1697; cells were challenged with toxin in the absence of 
additional treatment, in the presence of 0.1 mM GA, in the 
presence of 100 mM PBA, or in the presence of both 0.1 mM 
GA and 100 mM PBA; after 16 hr of intoxication, fluorescent 
output was recorded with a plate reader; Shiga toxin inhibits 
protein synthesis, so intoxicated cells will degrade the desta-
bilized green fluorescent protein and will not produce more of 
the protein, which thus generates a decrease in the fluorescent 
signal; the fluorescent output from cells not exposed to toxin 
was used to establish the maximal signal, and all other results 
were expressed as a percentage of this signal; the 
averages±standard errors of the means of four independent 
experiments with six replicate samples for each condition are 
shown. 
DETAILED DESCRIPTION OF THE PREFERRED 
EMBODIMENT 
The present invention will now be described more fully 
hereinafter with reference to the accompanying drawings, in 
which preferred embodiments of the invention are shown. 
Unless otherwise defined, all technical and scientific terms 
used herein have the same meaning as commonly understood 
by one of ordinary skill in the art to which this invention 
pertains. Although methods and materials similar or equiva-
lent to those described herein can be used in the practice or 
testing of the present invention, suitable methods and mate-
rials are described below. Any publications, patent applica-
tions, patents, and other references mentioned in this appli-
cation are incorporated herein by reference in their entirety. In 
case of conflict, the present specification, including any defi-
nitions, will control. In addition, it should be understood that 
the materials, methods and examples given are illustrative in 
nature only and not intended to be limiting. Accordingly, this 
invention may be embodied in many different forms and 
should not be construed as limited to the illustrated embodi-
ments set forth herein. Rather, these illustrated embodiments 
15 triggers the endoplasmic reticulum-associated degradation 
(ERAD) system to mediate CTAl export to the cytosol. In 
contrast, the currently accepted model of CTAl translocation 
treats CTAl as a stable protein that requires chaperone-me-
diated unfolding in the ER. The current model also propounds 
20 that CTAl stability provides the driving force for extraction 
from the ER, that is, the old model holds that as unfolded 
CTAl emerges from the Derlin-1 channel, it spontaneously 
refolds in the cytosol and thereby gains directionality for its 
movement across the ER membrane because the refolding 
25 would prevent it from sliding back into the channel. However, 
in our newly proposed model, because CTAl is actually in an 
unfolded conformation at 37° C., we hypothesize that a cyto-
solic chaperone must provide the driving force for CTAl 
export from the ER. Accordingly, under our new model, sta-
30 bilization of the heat-labile CTAl polypeptide within the ER 
could prevent its ERAD-mediated export to the cytosol and, 
consequently, could also prevent CT intoxication. Further-
more, based on our new model, CT passage into the cytosol 
and cellular intoxication could also be prevented by inhibition 
35 of the cytosolic chaperone that provides the driving force for 
CTAl export from the ER. 
Additionally, our soon to be published paper titled "Stabi-
lization of the Tertiary Structure for the Cholera Toxin Al 
Polypeptide Inhibits Toxin Dislocation and Cellular Intoxi-
40 cation" presents proof-of-principle for the concept of our new 
model. We used glycerol, a known "chemical chaperone" that 
stabilizes protein structures, to inhibit the thermal unfolding 
ofCTAl. Glycerol also prevented CTAl export to the cytosol 
(results not shown) and CT intoxication. However, glycerol is 
45 not a viable therapeutic option since it would be toxic to the 
patient. We therefore undertook a search for non-toxic poten-
tially effective drugs (see also, Perlmutter, D. H., Chemical 
Chaperones: A Pharmacological Strategy for Disorders of 
Protein Folding and Trafficking, Pediatric Research, 52(6), 
50 832-836). 
Our search identified sodium 4-phenylbutyrate (PBA) as a 
potential non-toxic drug candidate. PBA, like glycerol, is 
another chemical chaperone but it is tolerated by humans and 
is actually an FDA-approved drug for treating diseases 
55 related to urea cycle enzyme deficiencies. Our experimental 
work disclosed in the priority provisional application (docu-
ment titled "A Therapeutic Chemical Chaperone Inhibits 
Cholera Intoxication and Unfolding/Translocation of the 
Cholera Toxin Al Subunit'') showed that PBA prevents the 
60 thermal unfolding ofCTAl and also prevents CT intoxication 
of cultured cells. Experiments now underway, we predict will 
show that PBA prevents CTAl export from the ER into the 
cytosol. 
Since we hypothesize that this drug may have real thera-
65 peutic potential for treating CT, and possibly other toxin-
mediated diseases, we are further investigating if it also dem-
onstrates a CTAl inhibitory effect in a physiological model of 
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intoxication-the ilea! loop system. If, as expected, PBA 
blocks intoxication in ilea! loops, this would provide strong 
support for our new proposed mechanism of action of CTAl 
and how this toxin may be counteracted. 
A second anti-toxin therapeutic agent we have identified is 5 
geldanamycin (GA), an inhibitor ofhsp90. GA has received a 
attention as a potential anti-cancer agent (see the review 
article by Blagosklonny, M. V., Hsp-90-associated oncopro-
teins: multiple targets of geldanamycin and its analogs, Leu-
kemia (2002) 16, 456,462). GA itself was initially found to be 10 
too toxic for therapeutic use, but second generation GA 
derivatives have proven effective in phase I clinical trials. We 
theorized that because hsp90 is required for the endosome-
to-cytosol translocation of diphtheria toxin and the clostridial 
ADP-ribosylating toxins, GA might provide a good target for 15 
a therapeutic drug. See the following: Ratts et al., The cyto-
solic entry of diphtheria toxin catalytic domain requires a host 
cell cytosolic translocation factor complex, J. Cell Biol., 160 
(7), 1139-1150 (2003); Haug et al., The Host Cell Chaperone 
Hsp90 Is Essential for Translocation of the Binary 20 
Clostridium botulinum C2 Toxin into the Cytosol, J. Biologi-
cal Chem., 278(34), 32266-32274 (2003); Haug et al., The 
Host Cell Chaperone Hsp90 Is Necessary for Cytotoxic 
Action of the Binary Iota-Like Toxins, Infection and Immu-
nity, 72(5), 3066-3068 (2004); and Marissa V Powers and 25 
Paul Workman, Targeting of multiple signaling pathways by 
heat shock protein 90 molecular chaperone inhibitors, Endo-
crine-Related Cancer (2006) 13 S125-S135. 
Moreover, we have now shown by surface plasmon reso-
nance (SPR) that hsp90 interacts directly with CTAl and that 30 
this interaction is inhibited by GA. CT intoxication is also 
blocked in GA-treated cells (attached). We are further 
improving the translocation assay to determine if GA pre-
vents the ER-to-cytosol export of CTAl. We theorize that 
Hsp90 is the cytosolic chaperone that provides the driving 35 
force for extraction of CTAl and other ADP-ribosylating 
toxins from the ER. 
The data shown graphically in FIG. 1 also help to explain 
Table 1. The data in FIG. 1 are raw measurements from three 
biophysical techniques, near-UV circular dichroism (CD), 40 
fluorescence spectroscopy, and far-UV CD (from left to right, 
respectively, in the figure). Near-UV CD and fluorescence 
spectroscopy provide two different measures of protein ter-
tiary structure. Far-UV CD provides a measurement of sec-
ondary structure. Certain linear arrangements of amino acids 45 
will spontaneously assume common shapes known as a-he-
lices and ~-sheets. These shapes are the secondary structure 
of a protein. The linear order of amino acids is the primary 
structure. The overall three dimensional structure of a protein 
which is ordered around the secondary structures is the pro- 50 
tein tertiary structure. In the tertiary structure of a properly 
folded protein, the hydrophobic amino acids should be buried 
within the protein and protected from the aqueous environ-
ment. The measurements of tertiary structure detect the sol-
vent exposure of the hydrophobic amino acids; this is indica- 55 
tive of protein unfolding. Each line in the raw data shown in 
FIG. 1 (top 6 panels) represents a measurement at a different 
temperature, with the color shift from blue to red correspond-
ing to a shift in temperature from 18 to 65° C. The top row 
presents measurements taken forthe catalytic Al polypeptide 60 
of cholera toxin (CTAl), and the middle row are measure-
ments taken for CTAl in the presence of 100 µM PBA. The 
bottom row is an analysis of the top two rows in which protein 
unfolding is plotted as a function of temperature. Low Y axis 
values represent folded conformations of the toxin, while 65 
high Y axis measurements represent unfolded conformations 
of the toxin. The high values plateau when the final unfolded 
10 
state is reached. From these sigmoidal curves, we can calcu-
late how much initial protein structure remains at each tem-
perature. The point at which 50% of the initial structure is lost 
is called the transition temperature (Tm). It is the Tm values 
that are listed in the Table. The Figure of the raw data and 
unfolding curves only shows the data for 100 µM PBA, but we 
also ran experiments for 1 and 10 µM PBA. The processed 
data for these experiments are in the Table, which shows there 
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three CTAl structural parameters even at 1 µM PBA. Higher 
PBA concentrations provide a higher level of structural sta-
bilization, meaning higher temperatures are required to 
unfold CTAl. Interestingly, even in the presence of PBA the 
Tm values are still near physiological temperature. Given that 
even 1 µM PBA has some inhibitory effect on CT intoxica-
tion, this must mean that substantial unfolding of CTAl is 
required to trigger its export to the cytosol where its target 
resides. 
The graphs shown in FIG. 1 plot the cellular effect of CT 
intoxication. CT-treated cells generate elevated levels of 
cAMP which we measure. The maximal cAMP response for 
all conditions is set at 100%, and all other cAMP values are 
expressed as a percentage of this maximal value. Cells are 
treated with toxin for 2 continual hours before measurement, 
and PBA is added simultaneously with the toxin. The first 
graph is the result with 1 µM PBA, and the second graph is the 
result with 100 µM PBA. The control curves (results without 
PBA) differ from the two graphs because two different assay 
kits forusedforthe experiments, and the second kit (with 100 
µM PBA) has a better detection range. We are now standard-
izing all of our experiments by just using the second kit. 
Fold-resistance is determined from the half-maximal effec-
tive concentrations (toxin concentration that gives an effect 
50% of the maximum). For 1 µMPBA, we seea3.5-foldlevel 
of toxin resistance. We can't calculate fold resistance for 100 
µM PBA because in the presence of PBA we didn't reach a 
50% value even at the highest toxin concentration. So 100 µM 
PBA works pretty well, at least in cell culture. 
We have also conducted additional experiments to deter-
mine the binding affinity of PBA for CTAl. Although not 
shown here, the data indicate that PBA binds to CTAl and the 
CT holotoxin (which would include CTAl), but it does not 
bind to the cell-binding B subunit of CT. Accordingly, there is 
some specificity to the toxin-PBA interaction, which is unex-
pectedly surprising. PBA appears to bind to CTAl/CT with 
-100 µM affinity, which represents a very high affinity inter-
action (tight binding). 
Accordingly, this disclosure teaches that at least these two 
therapeutics, PBA and GA, are effective in suppressing entry 
of an AB-type bacterial toxin, particularly anADP-ribosylat-
ing toxin such as CTAl into the host cell cytosol and also 
mitigates or prevents toxicity to the cells themselves. Addi-
tionally, given the high degree of similarity between CT and 
E. coli LT we believe that in a prophetic example we can 
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studies found that glycerol preferentially stabilized the ter-
tiary structure of CTAl without having any noticeable effect 
on the thermal stability of its secondary structure. The ther-
mal disordering of CTAl tertiary structure normally preceded 
predict that PBA and GA may also be effective in blocking LT 
intoxication. Moreover, we also theorize it will be fruitful to 
test a combination of both PBA and GA. Since PBA and GA 
block separate steps in the translocation process, they may 
have an additive effect on toxin inhibition. 
The toxins/diseases which we initially expected might be 
inhibited by GA and/or PBA included the following: 
1. cholera toxin/cholera; 
2. E. coli heat-labile toxin/traveler's diarrhea; 
3. pertussis toxin/whooping cough; 
5 the perturbation of its secondary structure, but in the presence 
of 10% glycerol the temperature-induced loss of CTAl ter-
tiary structure occurred at higher temperatures in tandem with 
the loss ofCTAl secondary structure. The glycerol-induced 
stabilization of CTAl tertiary structure blocked CTAl dislo-
lO cation from the ER and instead promoted CTAl secretion into 
the extracellular medium. This, in turn, inhibited CT intoxi-
cation. Glycerol treatment also inhibited the in vitro degra-
dation of CTAl by the core 20S proteasome. Collectively, 
4. exotoxin A/infections with Pseudomonas aeruginosa 
(particularly in cystic fibrosis patients or in burn vic-
tims); and 
5. Shiga toxin/shigellosis and food-borne outbreaks of 
enterohemorrhagic E. coli (0157 :H7). 
The order shown for the toxins listed is the expected order 
15 
these findings indicate that toxin thermal instability plays a 
key role in the intoxication process and that an agent that 
increases the stabilization of CTAl tertiary structure is a of likelihood for drug-induced toxin resistance. GA inhibits 
Hsp90 function, and Hsp90 may specifically recognize and 
interact with ADP-ribosylating toxins. CT and LTare very 
similar ADP-ribosylating toxins, so that PBA and GA should 20 
work against both of them. Pertussis toxin is anADP-ribosy-
lating toxin and is very unstable, so there is a reasonable basis 
for expecting that both PBA and GA will work against this 
toxin. 
potential anti-toxin therapeutic drug. 
Introduction 
Cholera toxin (CT) is an AB5 protein toxin that ADP-
ribosylates and activates the stimulatory a subunit of the 
heterotrimeric G protein (Gsa).1·2 The catalytic A moiety of 
CT is synthesized as a CTA protein of 27 kDa molecular 
mass. Nicking of CTA by the Vibrio cholerae hemagglutinin 
Our experiments with exotoxinA (ETA) only showed weak 
drug-induced resistance, although we still need to test the 
PBA/GA combination treatment. ETA is also an ADP-ribo-
sylating toxin, so we expected GA to work against it. The 
stability of ETA is unknown, but our new model predicts all 
AB-type (catalytic A subunit, cell-binding B subunit) ER-
translocating toxins will have an unstable A chain. 
25 protease or other proteases generates a disulfide-linked 
CTA1/CTA2 heterodimer. Enzymatic activity is a property of 
the 22 kDa CTAl subunit, while the 5 kDa CTA2 subunit 
interacts non-covalently with the B pentamer and thereby 
tethers CTAl to the CTB domain. The cell-binding B moiety 
Shiga toxin is not an ADP-ribosylating toxin, thus, we 
expected a lower probability that GA would be effective 
against it. The stability of Shiga toxin is unknown, but we 
predict it is unstable and that it will, therefore, be affected/ 
inhibited by PBA. 
30 of CT is assembled from 12 kDa monomers as a homopen-
tameric ring-like structure that adheres to GM! gangliosides 
on the eukaryotic plasma membrane. 
A substantial portion of surface-bound CT is delivered to 
the lysosomes and degraded, but the functional pool of toxin 
35 is instead transported to the endoplasmic reticulum (ER) 
through a series of vesicular trafficking events. 3-6 The resi-
dent redox state of the ER reduces the CTA1/CTA2 disulfide 
bond, which then permits chaperone-assisted dissociation of 
PBA and GA did not inhibit ricin. Ricin is not an ADP-
ribosylating toxin, so we did not expect GA to have an effect. 
The unfolding of ricin A chain in the ER is facilitated by an 
interaction with the lipids of the inner leaflet of the ER mem- 40 
brane, so it may be that PBA cannot inhibit the assisted 
unfolding of a toxin A chain. 
Reviewing recent articles on chemical chaperones for 
potential drug candidates it appears that besides PBA, other 
chemical chaperones potentially useful in this invention 45 
include glycerol, deuterated water, DMSO, and trimethy-
lamine N-oxide (TMAO). These other reagents work in cell 
culture but, due to toxicity, not so well in patients. In general, 
there has been a shift to more specific "pharmacological 
chaperones" which are designed to only function against the 50 
targeted protein. PBA and the chemical chaperones are less 
specific than pharmacological chaperones and can affect 
many proteins. We expected that there would be non-toxic 
chemical chaperones other than PBA, but after a literature 
search it seems that PBA may be the only therapeutic chemi- 55 
cal chaperone presently available. 
A Therapeutic Strategy: Blocking Unfolding of Toxin A 
Chain Summary 
Cholera toxin (CT) moves from the cell surface to the 
endoplasmic reticulum (ER) by retrograde vesicular trans- 60 
port. The catalytic subunit of CT (CTAl) then crosses the ER 
membrane and enters the cytosol in a process that involves the 
quality control mechanism of ER-associated degradation 
(ERAD). The molecular details of this dislocation event are 
poorly characterized. Here, we report that thermal instability 65 
in the CTAl subunit-specifically, the loss ofCTAl tertiary 
structure at 37° C.-triggers toxin dislocation. Biophysical 
CTAl from CTA2/CTB5.
7-9 The isolated CTAl subunit sub-
sequently crosses the ER membrane and enters the cytosol 
where it interacts with Gsa· Activated Gsa stimulates adeny-
late cyclase function and the production of cAMP. This leads 
to the opening of chloride channels on the apical face of 
intoxicated intestinal epithelial cells; the osmotic movement 
of water which follows chloride efflux into the gut generates 
the profuse watery diarrhea of cholera.1 ·2 
To move from the ER to the cytosol, CTAl uses the ER-
associated degradation (ERAD) dislocation mechanism.9-13 
ERAD recognizes misfolded or misassembled proteins in the 
ER and exports them to the cytosol for degradation by the 26S 
proteasome. 14 CTAl export probably occurs through Sec61 
and/or Derlin-1 protein-conducting channels in the ER mem-
brane.15-17 Although CTAl is processed as an ERAD sub-
strate, it avoids the standard ERAD route ofubiquitin-depen-
dent proteasomal degradation because its arginine-over-
lysine bias limits the number of potential sites for ubiquitin 
conjugation. 18 Other AB toxins such as Shiga toxin and ricin 
also move from the cell surface to the ER and exploit ERAD 
for entry into the cytosol. 19·20 
Two major predictions have been derived from the ERAD 
model of CTAl dislocation: (i) the C-terminal hydrophobic 
region of CTAl (residues 162-192; the Al 3 subdomain) trig-
gers ERAD-mediated toxin entry into the cytosol; and (ii) the 
translocated pool of CTAl is stable in the eukaryotic cyto-
sol. 6021 It is hypothesized that components of the ERAD 
machinery interact with the CTAl 3 subdomain and subse-
quently unfold the toxin for passage into the cytosol.9 CTAl 
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is then thought to spontaneously refold in the cytosol, pro-
ducing a stable conformation that is resistant to proteasomal 
degradation. 18 
We have shown that the CTAl 3 subdomain is not required 
for toxin entry into the cytosol and that the translocated pool 5 
of CTAl is not stable in the cytosol. 10•22 Both observations 
may be linked to the unstable, heat-labile nature of the CTAl 
subunit.23 •24 CTAl is held in a stable conformation when 
associated with other components of the holotoxin, 24-26 but it 
can unfold spontaneously after dissociation from CTA2/ 10 
CTB5.
24 This unfolding event would activate the ERAD sys-
tem and thereby promote CTAl export to the cytosol. Follow-
ing dislocation into the cytosol, CTAl could retain significant 
enzymatic activity because of its association with host pro-
teins such as the ADP-ribosylation factors that serve as co- 15 
factors to enhance CTAl activity.23 •24•27 However, the struc-
tural state of the isolated CTAl subunit leaves it susceptible to 
ubiquitin-independent degradation by the core 20S protea-
some.24 With this model of toxin-ERAD interactions, an 
inherent physical property of the CTAl subunit (i.e., thermal 20 
instability) is linked to both toxin dislocation into the cytosol 
and toxin degradation in the cytosol. Our model suggests 
CTAl is processed as a typical misfolded/unfolded ERAD 
substrate, whereas a prevailing model of toxin dislocation 
treats CTAl as a stable protein that requires chaperone-as- 25 
sisted unfolding in order to move from the ER to the cytosol. 6· 
9.16.18.28 
According to our model, structural stabilization of the 
CTAl subunit will inhibit CTAl dislocation and thereby pre-
vent CT intoxication. The thermal stabilization of CTAl 30 
should also block its degradation by the 20S proteasome, 
which only acts upon unfolded substrates.29 To test these 
predictions, we examined the impact of glycerol on CTAl 
structure, CTAl dislocation/degradation, and CT intoxica-
tion. Glycerol is a chemical chaperone that stabilizes protein 35 
structures and is commonly used to disrupt ERAD-substrate 
interactions.30-34 Glycerol has also been shown, by an 
unknown mechanism, to protect cultured cells against intoxi-
cation with either ricin or Shiga toxin 2.35036 In this work we 
show that glycerol prevents the temperature-induced loss of 40 
CTAl tertiary structure, which in turn prevents CTAl dislo-
cation into the cytosol and productive intoxication. Glycerol 
also inhibited the in vitro degradation of CTAl by the 20S 
proteasome. These observations provide mechanistic insight 
into the molecular events underlying CTAl-ERAD interac- 45 
tions and suggest a new therapeutic approach for anti-toxin 
countermeasures. 
Results 
Effect of Glycerol on CTAl Protease Sensitivity 
14 
Coomassie staining. Since all protease treatments were per-
formed at 4 ° C., differential degradation of the toxin samples 
could only result from temperature-induced changes to the 
structure of CTAl. 
Previous work has shown that our reducing condition of 10 
mM ~-mercaptoethanol (~-ME) is sufficient for complete 
separation of CTAl from CTA2;24 this result was also con-
firmed for CTA1/CTA2 heterodimers incubated with 10 mM 
~-ME and 10% glycerol (FIG. 7(a)). Reduction of the CTAl/ 
CTA2 disulfide bond is necessary to examine the temperature 
dependence of CTAl protease sensitivity because the cova-
lent association of CTAl with CTA2 provides a degree of 
conformational stability to CTAl which prevents its proteoly-
sis by thermolysin.24 
The isolated CTAl subunit was largely resistant to ther-
molysin-mediated proteolysis when incubated at tempera-
tures up to 33° C., but CTAl shifted to a protease-sensitive 
state at 37° C. This was evidenced by a substantial weakening 
of the CTAl band in the gel when the toxin was preincubated 
at temperatures above 33° C. before thermolysin treatment 
(FIG. 7(b)). Little change in CTAl band intensities were 
observed in the temperature range of 4° C. to 41° C. for toxin 
samples treated with 10% glycerol, indicating that treatment 
with 10% glycerol prevented the transition of CTAl to a 
protease-sensitive state at 3 7° C. and 41 ° C. In contrast, under 
identical buffer conditions glycerol treatment did not prevent 
the thermolysin-mediated proteolysis of a-casein, a protein 
with an open and flexible conformation38 (data not shown). 
The inhibitory effect of glycerol on CTAl proteolysis was 
thus unlikely to result from a direct inhibition of thermolysin 
activity. Instead, glycerol treatment appeared to keep CTAl in 
a folded, protease-resistant conformation at 37° C. and 41° C. 
Effect of Glycerol on CTAl Thermal Stability 
Biophysical experiments were performed in order to 
directly examine the impact of glycerol on CTAl thermal 
instability (FIG. 8). Near- and far-UV circular dichroism 
(CD) measurements were conducted on Hise tagged CTAl in 
the absence or presence of 10% glycerol. Readings were 
taken during a step-wise increase in temperature from 18° C. 
to 65° C. Near-UV CD measurements detected the disorder-
ing ofCTAl tertiary structure (FIGS. 8(a) and 8(c)), while 
far-UV CD measurements detected the unfolding of CTAl 
secondary structure (FIGS. 8(b) and 8(d)). To avoid errors 
from sample-to-sample variability, both measurements were 
conducted near-simultaneously on the same sample. The data 
from these experiments were used to generate CTAl thermal 
unfolding profiles (FIGS. 8(e) and 8(1)) which were, in turn, 
used to calculate the amount of initial (18° C.) tertiary and 
secondary structure remaining in CTAl at various tempera-
As a first step toward evaluating the stabilizing effect of 
glycerol on CTAl structure, we employed a protease sensi-
tivity assay (FIG. 7). A final concentration of 10% glycerol 
was used in order to maintain consistency with other reports 
that have used this concentration of glycerol to disrupt 
ERAD-substrate and/or host-toxin interactions.31 -33•35•36 
Protease sensitivity assays are used to probe the folding state 
of a protein, as proteins often become more susceptible to 
proteolysis upon (partial) unfolding.9024037 Samples of the 
reduced CTA1/CTA2 heterodimer were incubated in the 
absence or presence of 10% glycerol for 45 minutes at 4 ° C., 
25° C., 33° C., 37° C., or41° C.All samples were then placed 
on ice and exposed to thermolysin, a metalloendoprotease 
that cleaves the peptide bonds in proteins at the surface-
exposed hydrophobic residues. EDTA and sample buffer 
were added after 45 minutes to halt the digests, and the 
samples were subsequently resolved by sodium dodecyl sul-
fate polyacrylamide gel electrophoresis (SDS-PAGE) with 
50 tures (Table 1, below). The tertiary structure of CTAl exhib-
ited a transition temperature (Tm) of34± 1 ° C. in the untreated 
control condition and a Tm of 39.5±1° C. in the presence of 
glycerol (Table 2). Untreated CTAl only retained 33% of its 
initial tertiary structure at 37° C., whereas glycerol-treated 
55 CTAl retained 58% of its initial tertiary structure at 37° C. In 
contrast, the thermal unfolding profile of CTAl secondary 
structure was not shifted by glycerol: in both the absence and 
presence of 10% glycerol, CTAl exhibited a secondary struc-
ture Tm of39±0.5° C. and retained-60% of its initial second-
60 ary structure at 37° C. These data delineate a significant effect 
of glycerol on the heat-sensitivity of CTAl tertiary structure. 
The thermal disordering of CTAl tertiary structure normally 
preceded the perturbation ofCTAl secondary structure, 24 but 
in the presence of 10% glycerol the temperature-induced loss 
65 of CTAl tertiary structure was shifted to higher temperatures 
and occurred in parallel with the loss of CTAl secondary 
structure. Thus, glycerol treatment preferentially increased 
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the thermal stability of the tertiary structure of CTAl while 
exerting little effect on the secondary structure of the protein. 
Effect of Glycerol on CTAl Dislocation 
According to our model, the thermal stabilization ofCTAl 
should block its export to the cytosol. A previously described 5 
assay28 for monitoring CTAl dislocation from the ER was 
used to test this prediction (FIG. 9(a)). HeLa cells incubated 
on ice for 30 minutes with 1 mg/ml of CT were chased for 2 
hours at 37° C. in toxin-free medium that lacked or contained 
10% glycerol. Previous studies have demonstrated that glyc- 10 
erol equilibrates across the plasma membrane with a t112 of 5 
minutes,32 while it takes about 45 minutes for a fraction of 
surface-bound CT to reach the ER.5 •16 Selective permeabili-
zation of the plasma membrane with digitonin was used to 
partition the toxin-treated cells into two fractions that con- 15 
tained either (i) the plasma membrane and intact intracellular 
membranes or (ii) the cytosol. Control experiments demon-
strated that protein disulfide isomerase (PDI), a soluble ER 
protein, was only found in the pellet fractions (i.e., ER and 
other membranes) of untreated and glycerol-treated cells. 20 
Furthermore, the cytosolic protein Hsp90 was found in the 
supernatant fractions (i.e., cytosol) of both untreated and 
glycerol-treated cells. Our fractionation procedure could thus 
clearly separate cell extracts into distinct organelle and cyto-
solic components. CTAl was only detected in the pellet frac- 25 
ti on after pulse labeling at 4 ° C., a temperature that blocks the 
endocytosis of surface-bound protein. However, as expected, 
a portion of surface-bound CTAl entered the cytosolic frac-
tion after a 2 hour chase at 3 7° C. Less CTAl was found in the 
cytosol of glycerol-treated cells than in the cytosol of 30 
untreated control cells (FIG. 9(a)). Semi-quantitative analy-
sis of our dislocation assay indicated that 23±8% of the total 
cellular pool of CTAl was present in the cytosolic fraction of 
untreated cells, and 7±4% of the total cellular pool ofCTAl 
was present in the cytosolic fraction of glycerol-treated cells 35 
(n=2). In the two individual experiments, glycerol treatment 
resulted in a 3-fold or 5-fold reduction in cytosolic CTAl. 
This indicated that the glycerol-induced stabilization of 
CTAl tertiary structure inhibited CTAl dislocation into the 
16 
effect: less CTAl was found in the cytosol of glycerol-treated 
cells than in the cytosol of untreated control cells. These 
collective observations provided additional support for our 
conclusion that the glycerol-induced thermal stabilization of 
CTAl prevented toxin dislocation to the cytosol. 
Effect of Glycerol on CTAl Secretion from Intoxicated Cells 
Misfolded or misassembled proteins and proteins with spe-
cific targeting determinants are effectively retained in the ER; 
all other proteins are packaged into vesicle carriers for trans-
port to the Golgi apparatus and beyond.14 Stabilization of the 
CTAl tertiary structure could therefore generate a folded 
toxin conformation that is recognized as secretory cargo and 
accordingly directed to vesicle traffic in the biosynthetic 
secretory pathway. In this case, glycerol treatment would 
result in the secretion of CTAl from intoxicated cells. To 
examine this possibility, SPR was used to detect CTAl in the 
extracellular medium of cells intoxicated in the absence or 
presence of 10% glycerol (FIG. 10). A minimal background 
signal was detected when the medium from unintoxicated 
HeLa control cells was perfused over a SPR sensor slide that 
had been coated with an anti-CTA antibody. A positive signal 
was detected when the medium from intoxicated cells was 
perfused over the sensor slide, and an even stronger signal 
was obtained from the medium of intoxicated cells incubated 
with 10% glycerol (FIG. 10). This indicated that, as previ-
ously reported, some amount of CTAl was released into the 
medium during the normal intoxication process. 3 However, a 
greater amount of CTAl was released into the medium when 
the toxin was stabilized by glycerol treatment (FIG. 10). No 
signal was detected when the experiment was performed with 
a sensor slide that had been coated with an anti-CTB anti-
body, thus demonstrating that the positive response from the 
CTA sensor slide did not result from the presence of CT 
holotoxin in the medium (data not shown). Similar results 
were obtained with Vero cells which, unlike HeLa cells, did 
not require GM! pre-treatment before intoxication (FIG. 16). 
Thus, the results of the HeLa secretion assay could not be 
attributed to GM! treatment or to cell-type specific effects. 
Because CTAl dissociates from CTA2/CTB5 in the 
cytosol. 40 ER,7-9 the secretion of CTAl from glycerol-treated cells 
strongly suggested that 10% glycerol did not inhibit traffick-
ing of the CT holotoxin to the ER. BfA, a drug that disrupts 
toxin transport to the ER,5 •39 was used to strengthen this 
Surface plasmon resonance (SPR) was used as an alterna-
tive method to detect the cytosolic pool of CTAl (FIG. 9(b )). 
Cytosolic fractions from intoxicated HeLa cells were pre-
pared as described above and perfused over an SPR sensor 
slide that was coated with an anti-CTA antibody. No signal 45 
was obtained from the cytosol of unintoxicated HeLa cells 
and from the cytosol of intoxicated cells treated with brefel-
din A (BfA), a drug that blocks toxin trafficking to the ER 
dislocation site.5 •39 Cells intoxicated in the presence of 10% 
interpretation. When the SPR secretion assay was repeated 
with cells exposed to BfA, we could not detect an appreciable 
amount ofCTAl in the medium ofintoxicated cells incubated 
in either the absence or presence of 10% glycerol (FIGS. 
ll(a) and b)). Thus, toxin trafficking to the ER was a prereq-
uisite for CTAl secretion. The kinetics of secretion also indi-
glycerol also failed to generate a positive cytosolic signal for 50 cated that intracellular toxin trafficking preceded the release 
CTAl (n=4). In contrast, we could reproducibly detect the ofCTAl into the medium: substantial amounts of extracellu-
cytosolic pool of CTAl from intoxicated but otherwise 
untreated control cells. When this assay was repeated as a five 
hour time course experiment, we recorded a time-dependent 
increase in the cytosolic pool ofCTAl. However, CTAl could 55 
not be detected in the cytosol of glycerol-treated cells at 1, 2, 
3, 4, or 5 hours of chase (FIG. 15). The apparent discrepancy 
between this result and the result presented for Western blot 
analysis of toxin dislocation, in which a minor pool of CTAl 
was detected in the cytosol of glycerol-treated cells (FIG. 60 
9(a)), stems from a procedural difference in the detection 
methods. For SPR analysis, the cytosolic fractions had to be 
diluted in order to obtain a sufficient volume of sample to run 
through the SPR instrument. This process apparently diluted 
the cytosolic pool of CTAl from glycerol-treated cells to a 65 
level below the threshold of detection for SPR. However, both 
SPR and Western blot analysis recorded the same qualitative 
lar CTAl were not detected until 90 minutes into the chase 
period, after which a greater amount of CTAl was released 
into the medium (FIGS. ll(a) and (b)). Analysis of these 
kinetic data and the data presented in FIG. 10 indicated that 
glycerol-treated cells secreted twice as much CTAl as the 
untreated control cells (FIG. ll(c)). Given that only a minor 
fraction (-5%) of cell-associated CT reaches the ER, 5 •39 a 
two-fold increase in CTAl secretion from glycerol-treated 
cells may represent the bulk of ER-localized toxin. It thus 
appeared that the glycerol-stabilized pool of CTAl was 
treated as secretory cargo rather than as an ERAD substrate 
and was accordingly released into the extracellular medium. 
Effect of Glycerol on CTAl Dissociation from the Holotoxin 
Results from the SPR secretion assays indicated that glyc-
erol treatment did not prevent CTAl dissociation from the 
holotoxin: if glycerol inhibited this event, CTAl would be 
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tethered to CTA2/CTB5 and could not enter the extracellular 
medium in a soluble state. An SPR-based experiment directly 
confirmed that glycerol treatment did not prevent CTAl dis-
sociation from theholotoxin (FIG.12). In this experiment, the 
CT holotoxin was appended to a GMl-coated sensor slide. 
Reduced PDI was then perfused over the sensor slide in the 
presence of 10% glycerol. Previous biochemical work has 
shown that reduced PDI facilitates the dissociation of CTAl 
from CTA2/CTB 5 . 
9 Our SPR experiment confirmed this PD!-
mediated event also occurs in the presence of 10% glycerol. 
Reduced PDI bound to CT and accordingly generated an 
increase in the measured refractive index. Although PDI was 
present in the perfusion buffer throughout the experiment, the 
refractive index began to drop precipitously 290 seconds into 
the experiments and eventually fell below the initial baseline 
value which represented the mass of the CT holotoxin. It thus 
appeared that both PDI and a component of the CT holotoxin 
were removed from the sensor slide. This would occur if PDI 
facilitated the dissociation of CTAl from CTA2/CTB5 : since 
the B pentamer was bound to the sensor slide, the release of 
CTAl from the holotoxin would wash both PDI and CTAl off 
the plate. To confirm that CTAl was removed from the sensor-
bound toxin, we perfused an anti-CTA antibody over the 
sensor slide. No signal was obtained with the anti-CTA anti-
body, thus indicating that CTAl was absent from the PDI-
treated toxin. In contrast, the anti-CTA antibody generated a 
robust signal when perfused over a sensor slide containing the 
intact CT holotoxin (data not shown).24 Additional control 
experiments with anti-CTB, anti-KD EL, or anti-PDI antibod-
ies demonstrated that CTB and the KDEL-tagged CTA2 sub-
unit, but not PDI, remained on the SPR sensor slide after the 
loss ofCTAl (data not shown). 
Effect of Glycerol on CT Intoxication 
18 
teasome for up to 20 hours in the absence or presence ofl 0% 
glycerol (FIG. 14(a)). Degradation of the reduced, isolated 
CTAl subunit by the 20S proteasome was detected after 3 
hours of co-incubation in our control condition and was 
5 nearly complete by 20 hours of co-incubation. However, sub-
stantial inhibition of CTAl degradation by the 20S protea-
some was observed when the toxin was incubated with both 
10% glycerol and the 20S proteasome. Glycerol did not 
inhibit a-casein degradation by the 20S proteasome (FIG. 
10 14(b )), which demonstrated that 10% glycerol did not directly 
impair the in vitro activity of the core 20S proteasome. The 
stabilization of CTAl tertiary structure by glycerol thus pre-
vented its ubiquitin-independent degradation by the 20S pro-
teasome. 
15 Discussion 
Toxin-ERAD interactions were originally thought to 
involve the C-terminal hydrophobic region of CTAl, but 
recent work has shown that this domain is not required for 
CTAl dislocation.22 An alternative ERAD trigger could 
20 derive from the unstable, heat-labile nature of the isolated 
CTAl polypeptide.23 •24 With this model, the global loss of 
CTAl structure that accompanies its dissociation from the 
holotoxin would identify it as a misfolded protein for ERAD 
processing. We accordingly predicted that the thermal stabi-
25 lization of CTAl would prevent its export to the cytosol and, 
hence, productive intoxication. The results of our experi-
ments with glycerol-treated cells, combined with biophysical 
studies on purified proteins, support this prediction. Our find-
ings identify the thermal unfolding ofCTAl tertiary structure 
30 as a requirement for ERAD recognition and thus provide a 
novel molecular mechanism for ERAD-mediated CTAl dis-
location. 
The glycerol-induced block of CTAl dislocation into the 
cytosol should prevent productive CT intoxication. To test 35 
this prediction, we monitored cAMP levels in untreated and 
glycerol-treated cells that had been continually exposed to 
varying concentrations of CT for 2 hours (FIG. 13). 
The thermal disordering of CTAl tertiary structure nor-
mally preceded the thermal denaturation of CTA 1 secondary 
structure by 5-6° C.24 However, here we show that in the 
presence of 10% glycerol the loss of CTAl tertiary structure 
was shifted to higher temperatures and occurred concomi-
tantly with the loss ofCTAl secondary structure. Glycerol did 
not affect the thermal perturbation of CTAl secondary struc-
ture, so the glycerol-induced effects on toxin processing 
apparently resulted from the specific stabilization of CTAl 
Glycerol-treated cells were indeed resistant to CT. 
Whereas a 50% maximal response was obtained with 3 ng of 40 
CT/ml in the untreated control cells, 35 ng of CT/ml was 
required to elicit the same effect in glycerol-treated cells. This 
effect was most likely due to direct inhibition of the CT 
intoxication process, as control experiments found that glyc-
erol did not inhibit forskolin-stimulated adenylate cyclase 45 
activity: cells treated with glycerol and forskolin produced 
105% of the cAMP signal generated by cells treated with 
forskolin alone. Furthermore, our SPR experiments demon-
strated that glycerol treatment did not prevent CT trafficking 
to the ER or CTAl dissociation from the holotoxin. Thus, the 50 
glycerol-induced inhibition of CT intoxication most likely 
resulted from the glycerol-induced block of CTAl disloca-
tion to the cytosol. 
tertiary structure. 
The near-UV CD signal around 280 nm that was used to 
track changes in CTAl tertiary structure involves contribu-
tions from both Trp and Tyr residues. Two of the three CTAl 
Trp residues that make substantial contributions to the near-
UV CD signal are present in the C-terminal domain that has 
previously been shown to be in a partially unfolded state. The 
glycerol-induced stabilization ofCTAl tertiary structure may 
therefore involve an effect on the C-terminal Al 3 subdomain. 
In this scenario, unfolding of the CTAl C-terminus would 
precede the loss of additional structure in the remainder of the 
toxin. Since the Al 3 subdomain is not necessary for CTAl 
dislocation, the temperature-induced loss of structure in other Effect of Glycerol on CTAl Degradation by the 20S Protea-
some 
CTAl is an in vitro substrate for ubiquitin-independent 
degradation by the 20S proteasome.24 This macromolecular 
complex forms the catalytic core of the 26S proteasome, 
which is generated by the addition of a l 9S cap to one or both 
ends of the barrel-shaped 20S proteasome. The function of 
the l 9S regulatory domain is ubiquitin recognition and ATP-
dependent substrate unfolding, so the core 20S proteasome 
can only degrade a limited number of unfolded proteins in a 
ubiquitin- and ATP-independent process.29 To determine 
whether the stabilization of CTAl tertiary structure inhibited 
toxin degradation by the 20S proteasome, we incubated a 
reduced CTA1/CTA2 heterodimer with the purified 20S pro-
55 regions of CTAl would serve as the ERAD trigger. This 
possibility is consistent with our interpretation of the avail-
able data-namely, that the thermal unfolding of CTAl ter-
tiary structure is required to activate the ERAD system. Addi-
tional structural studies will delineate the process of CTAl 
60 thermal unfolding which begins with the loss of tertiary struc-
ture. Here, we focused on the disruption of host-toxin inter-
actions resulting from the glycerol-induced stabilization of 
CTAl tertiary structure. 
Control conditions ensured that the glycerol-induced 
65 effects were due to the impact of glycerol on CTAl structure 
rather than to the action of glycerol on other components of 
the experiment. For example, we used a-casein, a protein with 
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a flexible and open structure,38 to demonstrate that glycerol 
did not directly inhibit the proteolytic activities of thermol-
ysin or the 20S proteasome. Additional experiments demon-
strated that glycerol treatment did not disrupt (i) holotoxin 
trafficking to the ER; (ii) chaperone-assisted dissociation of 
CTAl from CTA2/CTB5 ; (iii) secretion of the dissociated 
CTAl subunit; or (iv) cAMP production from activated ade-
nylate cyclase. Other studies have further shown that glycerol 
treatment does not affect the vesicular transport of secretory 
cargo, N-linked glycosylation in the endomembrane system, 10 
the functioning of chloride charmels, or the ERAD-indepen-
dent ER dislocation of the A subunit from Haemophilus 
ducreyi cytolethal distending toxin.32-34•40 Thus, the impact 
of glycerol on CTAl processing is highly unlikely to result 
from generic cellular effects. It instead appears to have 15 
resulted specifically from the stabilization of CTAl tertiary 
structure. 
20 
thermal disordering ofCTAl tertiary structure. The slow rate 
ofCTAl turnover in vivo, which under normal circumstances 
does not impact intoxication, 18 most likely reflects inefficient 
processing by the 20S variant of the proteasome and/or CTAl 
association with stabilizing host proteins such as the ADP-
ribosylation factors. 23 "24 
Our collective data indicate that CTAl thermal instability 
plays an essential role in the intoxication process. Thus, the 
thermal stabilization ofCTAl is a novel target for anti-toxin 
therapeutics. We have provided proof-of-principle for this 
concept by demonstrating that the glycerol-induced stabili-
zation of CTAl tertiary structure blocks toxin dislocation 
from the ER and productive intoxication. Exposure to high 
concentrations of glycerol is not a viable therapeutic option, 
but other chemical chaperones or target-specific "pharmaco-
logical chaperones" can stabilize protein conformations with-
out toxic side-effects.42 Other ER-dislocating toxins also 
contain thermally unstable A chains,37043044 so the use of 
chemical or pharmacological chaperones for toxin thermal 
There is one established case in which glycerol treatment 
does have a general effect on cellular events: chemical chap-
erones such as glycerol stabilize the folding intermediates in 
protein biogenesis, and this has been shown to alter the pro-
cessing of many ERAD substrates.30-34 CTAl therefore acts 
20 stabilization may represent a new, general strategy for anti-
toxin treatments. 
Materials and Methods 
Chemicals, thermolysin, a-casein, rabbit anti-CTA anti-
body, and ganglioside GM! were purchased from Sigma-
as a typical misfolded/unfolded ERAD substrate, which con-
tradicts a prevailing model oftoxin-ERAD interactions that 
treats CTAl as a stable protein.6·9 •18•18•28 
Glycerol treatment did not prevent CT trafficking to the ER 
25 Aldrich (St. Louis, Mo.). CT was purchased from List Bio-
logical Laboratories (Campbell, Calif.). Cell culture reagents 
were purchased from Invitrogen (Carlsbad, Calif.). ATP and 
the purified CTA1/CTA2 heterodimer were purchased from 
or CTAl dissociation from the holotoxin. However, glycerol 
treatment did prevent the ER-to-cytosol dislocation ofCTAl. 
CT intoxication was consequently impaired in glycerol-
treated cells. These effects, which specifically resulted from 30 
the stabilization of CTAl tertiary structure, demonstrated the 
functional consequences of CTAl thermal stabilization. The 
trigger for ERAD-mediated dislocation thus appears to derive 
from a global loss of CTAl tertiary structure rather than from 
the presence of a specific domain or motif within the toxin. As 35 
such, CTAl does not masquerade as misfolded protein to 
activate the ERAD system. CTAl is instead recognized as an 
ERAD substrate because, upon holotoxin disassembly, the 
thermal disordering of its tertiary structure produces an 
unfolded toxin conformation. 
Calbiochem (La Jolla, Calif.). The purified 20S proteasome 
was from Boston Biochem (Cambridge, Mass.). [35S]me-
thionine was purchased from Perkin-Elmer (Boston, Mass.). 
Rabbit anti-Hsp90 and anti-PDI antibodies were purchased 
from Stress gen Bioreagents Corp. (Victoria, BC Canada); the 
horseradish peroxidase-conjugated goat anti-rabbit IgG anti-
body was from Jackson Immunoresearch Laboratories Inc. 
(West Grove Pa.); and Talon beads were from Clontech Labo-
ratories (Mountain View, Calif.). 
Protease Sensitivity Assay 
A master mix containing 6 mg of CTA1/CTA2, 10 mM 
40 6-ME, and 20 mM sodium phosphate (pH 7 .0) was prepared 
in a volume of 120 ml. A second master mix was prepared as 
above but with a final concentration of 10% glycerol. The 
mixes were divided into 20 ml aliquots and incubated at 4 ° C., 
25° C., 33° C., 37° C., or 41° C. for 45 minutes. The aliquots 
The thermal stabilization of CTAl blocked its ERAD-
mediated dislocation to the cytosol and instead promoted its 
secretion into the extracellular medium. This suggested that 
the stabilized pool of CTAl was not retained in the ER of 
glycerol-treated cells but was instead treated as normal secre-
tory cargo and released into the medium. A relatively small 
portion of cell-associated CT (-5%) reaches the ER, 5 •39 so the 
two-fold increase in CTAl secretion from glycerol-treated 
cells may represent the bulk of ER-localized toxin. Since the 
secreted pool of CTAl was not linked to its cell-binding B 
subunit, it could not reassociate with target cells and was 
therefore functionally inactive. The release of CTAl from 
glycerol-treated cells would also prevent its accumulation in 
the ER and any resulting ER stress response. Given these 
considerations, it appears thatA chain thermal stabilization is 55 
a promising anti-toxin therapeutic strategy. 
CTAl is degraded in vivo by a relatively slow, ubiquitin-
independent proteasomal mechanism. This process likely 
involves the core 20S proteasome, which can degrade CTAl 
45 were then placed on ice for 10 minutes, after which 2 ml of 
thermolysin was added to all the samples for a 1 hour incu-
bation at 4 ° C. Thermolysin, prepared as a 1 Oxstock in 50 mM 
CaC12 and 100 mM Hepes (pH 8.0), was added to a final 
concentration of 0.04 mg/ml. Digestions were halted by the 
50 addition of ethylenediaminetetraacetic acid (EDTA) to a final 
concentration of 10 mM. Samples were analyzed by SDS-
PAGE with 15% polyacrylamide gels. Coomassie staining 
was used to visualize the samples. 
CTA1-His6 Purification 
in an ATP- and ubiquitin-independent marmer in vitro.24 The 60 
glycerol-induced inhibition ofCTAl degradation by the 20S 
proteasome indicated that the loss of toxin tertiary structure is 
responsible for targeting CTAl to the 20S proteasome. This 
interpretation is consistent with a previous report that con-
cluded the 20S proteasome recognizes substrates with disor- 65 
dered tertiary structures.41 Collectively, these data suggest 
that CTAl degradation in the host cell cytosol results from the 
Escherichia coli strain BL21 pLysS was transformed with 
an inducible CTA1-His6 expression plasmid
22 and grown at 
37° C. in I liter Luria-Bertani broth to anA600 of0.6. CTA1-
His6 expression was induced by addition of 1 mM IPTG to the 
growth medium. The cells were pelleted after 4 hrs of induc-
tion, resuspended in extraction buffer (20 mM Tris-HCl, pH 
7.0, 300 mM NaCl, 0.1% Triton X-100, 1% deoxycholate, 
100 mg/ml of lysozyme, and 8 M urea), and lysed with three 
freeze-thaw cycles. The insoluble lysate fraction was 
removed with a 30 min, 12,000xg spin. The soluble fraction 
was then supplemented with a protease inhibitor cocktail and 
incubated in batch with Talon resin for 30 min at room tem-
perature. Unbound material in the supernatant was removed 
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with a 5 min spin at 700xg, and the resin was washed four 
times with extraction buffer containing 600 mM NaCl. To 
elute the bound toxin, the resin was placed in a column and 
exposed to increasing concentrations of imidazole in extrac-
tion buffer(lO, 15, 20, 25, 35, 40, 45, and lOOmMimidazole; 
2 mis for each concentration). Fractions of 0.5 ml volume 
were collected and analyzed by SDS-PAGE. Before experi-
mental use, the fractions containing purified CTA1-His6 were 
dialyzed against five changes of 500 ml sodium phosphate 
buffer (pH 7.4) in order to facilitate the refolding ofCTAl: the 10 
first step was for 2 hr at room temperature in 6 M urea buffer; 
the second step was overnight at 4 ° C. in 4 M urea buffer; the 
third step was for 2 hrs at 4 ° C. in 2 M urea buffer; the fourth 
step was for 1 hr at 4 ° C. in urea-free buffer; and the last step 
was for 20 min at 4° C. in urea-free buffer. Slide-a-lyzer 3500 15 
MWCO dialysis cups (Pierce, Rockford, Ill.) were used for 
the procedure. After dialysis, CTA1-His6 was used immedi-
ately for experimentation. 
CD Measurements 
A J-810 spectrofluoropolarimeter (Jasco Corp., Tokyo, 20 
Japan) with a Jasco PFD-425S Peltier temperature controller 
was used to study the temperature-dependent unfolding of 
CTA1-His6 . Near- and far-UV CD measurements were per-
formed with a 4-mm optical path-length rectangular quartz 
cuvette at a protein concentration of 73 mg/ml in 20 mM 25 
sodium borate buffer (pH 7.4) containing 150 mM NaCl. 
Thermal unfolding was carried out in the temperature range 
of 18-65° C. Samples were equilibrated for 4 minutes at each 
temperature, followed by measurements of CD spectra from 
195 to 325 nm. Five scans were recorded and averaged per 30 
spectrum. The observed ellipticity was converted to mean 
residue molar ellipticity, [8], in units of degreesxcm2 xdmo1- 1 
using [8]=8 06)cnre), where 8 obs is the measured ellipticity in 
millidegrees, c is the molar concentration of the protein, nres 
is the numberofamino acid residues in the protein, and I is the 35 
optical path-length in millimeters. The temperature-depen-
dent protein unfolding data were analyzed as previously 
described.24 The thermal unfolding profiles for TA1-His6 
were nearly identical to the profiles reported for native CTAl, 
which in the reduced state exhibited a secondary structure Tm 40 
of37.5° C. and a tertiary structure Tm of32° C.24 
22 
for analysis by SPR, and cells were lifted from the plate using 
750 ml of0.5 mM EDTA in PBS. Both wells for each condi-
tion were added to a single microcentrifuge tube which was 
spun at 5,000xg for 5 minutes at room temperature. The 
supernatant was discarded, and the cell pellet was resus-
pended in 100 ml of0.04% digitonin in HCN buffer (50 mM 
HEPES, pH 7.5, 150mMNaCI, 2 mMCaCl2 , lOmMN-eth-
ylmaleimide, and a protease inhibitor cocktail) for a 10 
minute incubation at 4° C. The digitonin-treated cells were 
spun at 16,000xg for 10 minutes at room temperature, after 
which the supernatant (i.e., cytosolic fraction) was collected 
and placed in a fresh microcentrifuge tube. For experiments 
involving Western blot analysis, 120 ml of lx sample buffer 
was added to the pellet and 20 ml of 4x sample buffer was 
added to the supernatant. 
Western Blot 
25 ml samples resolved by SDS-PAGE with 15% polyacry-
lamide gels were subsequently transferred to a PVDF mem-
brane. The membrane was incubated overnight at 4 ° C. with 
primary antibody (rabbit anti-Hsp90 at 1:20,000 dilution; 
rabbit anti-PDI at 1:5,000 dilution; or rabbit anti-CTA at 
1 :20,000 dilution). The membrane was then incubated at 
room temperature for 30 minutes with a secondary antibody 
(horseradish peroxidase-conjugated goat anti-rabbit IgG at 
1 :20,000 dilution). ECL Plus Western blotting detection 
reagents (GE Healthcare) were used for protein detection 
according to the manufacturer's instructions. Separate blots 
were run for each protein. 
For semi-quantitative analysis of our dislocation assay, the 
amount of cytosolic CTAl was calculated with the following 
equation: % cytosolic CTAl =CTAl supernatant signal/ 
[CTAl supernatant signal+CTAl pellet signal]. This calcula-
tion provides an internal control, as the amount of cytosolic 
CTAl is expressed as a ratio of total cell-associated CTAl for 
each experimental condition. Thus, there is no direct com-
parison of band intensities between separate cell extracts 
representing control and experimental conditions (i.e., 
+/-glycerol treatment). 
SPR Analysis 
Experiments were performed with a Reichert (Depew, 
N.Y.) SR7000 SPR Refractometer. To generate sensor slides 
coated with an anti-CTA antibody, an EDC-NHS activation 
buffer was perfused over a Reichert gold-plated glass slide for 
10 min at a flow rate of 5 ml/min. The same flow rate was used 
The change in the near-UV CD signal at 280 nm reflects 
two things: the local environment ofTrp and Tyr residues, and 
the conformation of the side chains of these residues. 
Changes in the local environment are caused by changes in 
the protein tertiary structure. A more tightly packed tertiary 
structure brings the main chain Ca atoms closer to the aro-
matic side chains and makes their local environment more 
chiral, thus affecting the aromatic side chain CD signal. As 
such, the changes in the near-UV CD signal around 280 nm 
reflect (i) changes in the local environment of Trp and Tyr 
residues and, thus, the protein tertiary structure; and (ii) the 
conformations of Trp and Tyr side chains. We accordingly 
interpreted the changes in this signal in terms of protein 
tertiary structure. 
45 for all steps of the procedure. A 5 min wash with PBS (pH 7.4) 
containing 1 % TritonX-100 (PBST) was used to remove the 
activation buffer, after which an anti-CTA antibody at 1 :2000 
dilution in PBST was perfused over the slide for 15 min. 
Unbound antibody was removed with a 5 min PBST wash, 
Dislocation and Secretion Assays 
HeLa cells were seeded into 6 well plates and grown over-
night to a density of approximately 10,000 cells/well. Dupli-
cate wells were used for each condition. To begin the experi-
ment, the cells were incubated for 1 hour at 37° C. in serum-
free medium containing 100 ng/ml of ganglioside GM!. This 
medium was subsequently replaced with serum-free medium 
containing 1 mg/ml of CT. After a 30 minute incubation at 4 ° 
C., the cells were washed twice with phosphate buffered 
saline (PBS) and placed in toxin/serum-free medium that 
either lacked or contained 10% glycerol. The cells were then 
incubated for 2 hours at 3 7° C. Media samples were collected 
50 and the remaining active groups on the sensor slide were 
deactivated with a 3 min exposure to ethanolamine. 
To detect the cytosolic or secreted pools of CTAl, PBST 
(pH 7.4) was perfused over the CTA sensor slide for 5 min to 
establish a baseline reading. Experimental samples were then 
55 flowed over the sensor slide. Before use, cytosolic fractions 
from the dislocation assay were diluted in HCN buffer to a 
final volume of 1 ml. This step was necessary in order to 
obtain a sufficient volume of sample to run through the SPR 
instrument. For the secretion assay, all media samples were 
60 standardized to a final concentration of 5% glycerol (2 ml 
final volume) in order to eliminate any differential effect 
glycerol might have on detection by the SPR instrument. CTA 
standards diluted in HCN buffer or 5% glycerol were used for 
the dislocation assay and secretion assay, respectively. Iden-
65 ti cal results were obtained for CTA standards diluted in either 
HCN buffer or HCN buffer containing cellular extracts gen-
erated from unintoxicated cells (data not shown); this dem-
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onstrated that the data obtained from our dislocation assay 
were not affected by the presence of cytosol. Experimental 
samples were removed from the perfusion buffer after expo-
sure to the SPR sensor for approximately 180 sec. This pro-
cess usually results in a loss of signal which reflects the 5 
dissociation rate constant. However, for these experiments, 
the strong antibody-antigen interaction prevented any signifi-
cant loss of signal due to ligand dissociation. After each 
reading, bound ligand was stripped from the sensor slide with 
extracts were then transferred to microcentrifuge tubes and 
allowed to air dry at room temperature. cAMP levels were 
determined using an [1 25I]cAMP competition assay as per 
manufacturer's instructions (Amersham Biosciences). The 
basal levels of cAMP determined from unintoxicated cells 
were background-subtracted from the values obtained for 
toxin-treated cells; the maximal response from all conditions 
was arbitrarily set to 100%; and all other results were 
expressed as ratios of that 100% value. All conditions were 
performed in triplicate. a 5 min PBSTwash at pH 6.0. The Reichert Labview software 10 
was used for data collection. 20S Proteasome Assay 
Preliminary experiments found that the pellet fractions 
from our dislocation assay produced SPR signals that were 
off-scale in relation to the weaker signals from the cytosolic 
fractions. We therefore focused on the relative signal intensi-
ties of the cytosolic fractions. The disparity between 
organelle and cytosol signals for CTAl was consistent with 
the small fraction of cell-associated CTAl ( -5%) that reaches 
the ER and, subsequently, the cytosol. 5 •39 An additional con-
trol experiment demonstrated that the cytosolic fractions did 
not contain a factor that inhibited the detection of CTAl: 
nearly identical SPR signals were obtained from 10 ng/ml of 
CTA in buffer and from 10 ng/ml of CTA that had been added 
to a cytosolic fraction obtained from unintoxicated HeLa 
cells. 
The association rate constant derived from SPR data is 
directly proportional to ligand concentration.45 Thus, to 
determine the amount of CTAl secreted from intoxicated 
cells, association rate constants were calculated for the SPR 
data obtained from the experimental samples of FIG. 4, from 
the 120 min experimental samples from FIGS. S(a) and S(b), 
and from the ten-fold serial dilutions of purified CTA that 
were perfused over the sensor slide as controls for FIGS. 4 
and 5. The BioLogic (Campbell, Australia) Scrubber 2 soft-
ware was used to derive the association rate constants from 
our SPR data. The association rate constants for the CTA 
standards were plotted as a function of protein concentration. 
The slope of the resulting standard curve was then used to 
calculate the concentrations of CTAl in untreated and glyc-
erol-treated media samples. 
A 100 ml master mix was prepared with 1 µg 20S protea-
some, 5 µg substrate, 3 mM ATP, 10 mM ~-ME, 10 mM 
MgCl2 , 100 mM KC!, 0.1 mM CaCl2 , and 50 mM Hepes (pH 
15 7 .5). A second master mix was prepared as above but with a 
final concentration of 10% glycerol. The mixtures were 
placed at 37° C., and 20 ml aliquots were removed at 0, 4, 8, 
and 20 hours of incubation. Samples were analyzed by SDS-
PAGE with Coomassie staining. 
20 Hsp90 is Required for Transfer of the Cholera Toxin Al 
Subunit from the Endoplasmic Reticulum to the Cytosol 
Cholera toxin (CT) is an ABS toxin that moves from the 
cell surface to the endoplasmic reticulum (ER) by retrograde 
vesicular transport. In the ER, the catalytic Al subunit disso-
25 ciates from the rest of the toxin and enters the cytosol by 
exploiting the quality control system of ER-associated deg-
radation (ERAD). The driving force for CTAl dislocation 
into the cytosol is unknown. Here, we demonstrate that the 
cytosolic chaperone Hsp90 is required for CTAl passage into 
30 the cytosol. Hsp90 bound to CTAl in an ATP-dependent 
manner that was blocked by geldanamycin (GA), an estab-
lished Hsp90 inhibitor. CT activity against cultured cells was 
also blocked by GA, as was the ER-to-cytosol export of 
CTAl. Experiments using N-ethylcarboxamidoadenosine 
35 (NECA), a drug that inhibits ER-localized GRP94 but not 
cytosolic Hsp90, confirmed that the inhibitory effects of GA 
resulted specifically from the loss of Hsp90 activity. GRP94 
is glucose-regulated protein of 94 kDa, a major luminal con-
stituent of the endoplasmic reticulum and paralog of Hsp90; 
40 by amino acid homology, Grp94 is about 60% homologous 
and 50% identical to Hsp90a. This work establishes a func-
tional role for Hsp90 in the ERAD-mediated dislocation of 
CTAl. 
For SPR experiments using PDI and the CT holotoxin, a 
gold plate sensor was coated with the GM! ganglioside recep-
tor of CT by a procedure described for the coating of ELISA 
plates.46 CT was then bound to the GMl-coated sensor by 
perfusing 1 ml of CT (10 mg/ml) over the slide for 15 min at 45 
a flow rate of5 ml/min. The CT sensor was equilibrated at 37° 
ERAD substrates are extracted from the ER through a 
mechanism that often involves the AAA ATPase Cdc48/p97. 
However, p97 appears to play a minimal role in CTAl dislo-
cation. An alternative model has proposed a ratchet mecha-
nism which involves the spontaneous refolding of CTAl as it 
enters the cytosol. Recent CTAl structural studies do not 
C. in PBST and 10% glycerol for 10 min at a flow rate of 45 
ml/min. The SPR instrument was then calibrated with a base-
line measurement corresponding to the mass of the bound CT 
holotoxin. PDI was subsequently perfused over the sensor at 50 
a flow rate of 45 ml/min. PDI was diluted to a final concen-
support this model, as it has been shown that the isolated 
CTAl subunit is a disordered, thermally unstable protein. 
tration of 100 mM in PBST containing 10% glycerol and 1 
mM GSH. After 420 seconds, the PDI injection was replaced 
with an identical PDI buffer that also contained 80 mM of an 
Since CTAl is in a partially unfolded conformation at 37° C., 
an as yet unidentified host protein must provide the driving 
force for CTAl extraction from the ER. 
anti-CTA antibody. This PDI/antibody mixture was perfused 55 
over the sensor slide at a flow rate of 45 ml/min for 420 
Hsp90 functions in toxin translocation across the endoso-
mal membrane, but its potential role in ERAD-mediated toxin 
dislocation has not been examined. To address this issue, 
surface plasmon resonance (SPR) was used to determine 
whether Hsp90 could directly interact with the isolated CTAl 
seconds. Control experiments demonstrated that holotoxin 
disassembly did not occur upon exposure to either 1 mM GSH 
alone or to PDI in the absence of GSH. 
Toxicity Assay 
CHO cells were seeded into 24 well plates and grown 
overnight to 80% confluency. The medium was removed and 
replaced with serum-free medium containing the stated con-
centrations of CT in the absence or presence of 10% glycerol. 
After a 2 hour incubation, the cells were washed with PBS and 
exposed to 0.25 mL of ice-cold acidic ethanol (1 M HCI: 
100% EtOH at a 1: 100 ratio) for 15 minutes at 4 ° C. The cell 
60 subunit. Hsp90 binding to CTAl occurred in an ATP-depen-
dent marmer that was blocked by GA (FIG. 17A). The inter-
action between CTAl and Hsp90-ATP was not affected by 
NECA, a drug that inhibits GRP94 but not Hsp90 (FIG. 17A). 
GRP94, an ER-localized Hsp90, also bound to CTAl in an 
65 ATP-dependent process that was blocked by both GA and 
NECA (FIG.17B). The interaction between Hsp90 andCTAl 
was much stronger than the interaction between GRP94 and 
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fused over a SPR sensor slide that had been coated with an 
anti-CTA antibody (FIG. 20B). A negligible background sig-
nal was obtained from unintoxicated cells, whereas cells 
intoxicated in the absence of drug treatment produced a 
CTAl: Hsp90 bound to CTAl with a KD of 7 nM, whereas 
GRP94 bound to CTAl with a KD of 292 nM (FIG. 18 and 
Table 2). The specific, high-affinity interaction between 
Hsp90-ATP and CTAl indicated that Hsp90 could be 
involved with the CT intoxication process. 
To detect a functional role for Hsp90 in CT intoxication, 
CT toxicity assays were performed in the presence or absence 
of GA (FIG. 19A). CT activates Gsa, which in tum stimulates 
the activity of adenylate cyclase and the production of cAMP. 
CHO cells treated with GA exhibited substantial resistance to 
CT. In contrast, NECA-treated cells produced the same 
response to CT as the untreated cells. GA-induced toxin 
resistance was therefore due to the inactivation of Hsp90 
rather than to the inactivation of GRP94. NECA-treated cells 
were resistant to ricin, another AB toxin that uses the ERAD 
system for A chain dislocation to the cytosol (FIG. 19B). This 
observation was consistent with published results and dem-
onstrated that NECA was functional at the concentration used 
5 response that was equivalent the signal from the 0.1 ng/ml 
CTA standard. Cells intoxicated in the presence of NECA 
produced a response comparable to the response from cells 
intoxicated in the absence of drug treatment. In contrast, cells 
intoxicated in the presence of GA produced a weak SPR 
10 signal that was much less than the signal obtained from the0.1 
ng/ml CTA standard. 
Recently, Hsp90 was shown to be involved with the rena-
turation of an unfolded protein that had passed from the cell 
surface to the ER and from the ER to the cytosol. The Hsp90-
in our CT assay. Inactivation ofHsp90 thus provided cellular 
protection against CT. Additional control experiments dem-
onstrated that GA did not inhibit the forskolin-induced eleva-
tion of intracellular cAMP: cells treated with GA and forsko-
15 assisted refolding of denatured proteins may be linked to its 
dislocation activity: by coupling dislocation with refolding, 
Hsp90 would prevent the (re )folded CTAl protein from slid-
ing back into the dislocation pore. This ratchet mechanism 
would thus provide the driving force for CTAl dislocation. 
lin produced 100±2% of the cAMP levels recorded for cells 
treated with forskolin alone (n=3). Forskolin activates adeny-
late cyclase without the input of Gsa, so this observation 
demonstrated that GA did not directly inhibit the production 
of cAMP by adenylate cyclase. 
20 Although a previous report had suggested that the ATP-de-
pendent dislocation of CTAl does not require cytosolic fac-
tors, we and others have detected a membrane-associated 
pool of Hsp90 which may have been purified with the 
microsomal preparation used in that study. Our work clearly 
25 shows that Hsp90 exhibits a high affinity interaction with 
CTAl, and that the GA-induced disruption of this interaction 
inhibits both CTAl dislocation and CT intoxication in vivo. 
GA also inhibited CT activity in the ilea! loop model of 
intoxication (FIG. 19C). Surgically sealed sections of intes-
tine were injected with 1 mg of CT in the absence or presence 30 
of GA. Following a time interval, the CT-injected loop dis-
played the distended morphology indicative of water accu-
mulation resulting from productive intoxication. In contrast, 
substantially less fluid accumulation was observed in the loop 
that was injected with both CT and 1 mM GA. GA derivatives 35 
have also been evaluated as anti-cancer agents in phase I 
clinical trials. The protective effect of GA in a physiological 
model of intoxication suggests that it could also be used as a 
therapeutic to prevent or treat cholera. 
Toxin resistance can result from an inhibition of toxin 40 
dislocation from the ER to the cytosol. To determine if GA 
blocked toxin export to the cytosol, we used an established 
dislocation assay to monitor the appearance of CTAl in the 
cytosol of intoxicated HeLa cells (FIG. 4). Like CHO cells, 
GA-treated HeLa cells were protected from CT (data not 45 
shown). After a 30 minute exposure to CT at 4 ° C., HeLa cells 
were chased for two hours at 37° C. in the absence of addi-
tional toxin. Separate organelle and cytosol fractions were 
then collected from digitonin permeabilized cells. Control 
experiments demonstrated the fidelity of our fractionation 50 
protocol: Western blot analysis detected the majority of 
Hsp90 in the supernatant (i.e., cytosolic) fraction, while pro-
tein disulfide isomerase (PDI), a soluble ER protein, was 
found exclusively in the pellet fraction which contained the 
intact ER and other membranes (FIG. 20A). The distributions 
ofHsp90 and PDI were unaffected by treatment with GA or 
NECA. In comparison to the untreated control cells, the dis-
tribution of CTAl in the cytosol of intoxicated cells was also 
unaffected by NECA treatment. However, GA-treated cells 
contained less cytosolic CTAl than either untreated or 60 
NECA-treated cells. It thus appeared that Hsp90 function was 
required for efficient passage of CTAl into the cytosol. 
55 
To strengthen our Western blot analysis with a more sen-
sitive detection method, we employed the technique of SPR. 
HeLa cells exposed to CT at 4 ° C. were again fractionated into 65 
membrane and cytosolic components after a 2 hour chase at 
37° C. In this experiment, the cytosolic fractions were per-
Hsp90 is also involved with ricin intoxication, although in 
this case Hsp90 apparently prepares the catalytic toxin A 
chain for proteasomal degradation. The GA-induced inacti-
vation ofHsp90 thus allows ricinA chain to accumulate in the 
cytosol and thereby generates cellular sensitization to ricin. In 
contrast, we have shown that GA-treated cells are resistant to 
CT. The dislocation of ricinA chain also involves GRP94 and 
p97 whereas these proteins do not appear to be active in CTAl 
dislocation. Thus, while both CTAl and ricinA chain exploit 
ERAD for passage into the cytosol, distinct molecular events 
are involved with the dislocation of the two toxins. 
Hsp90 has been shown to maintain membrane-embedded 
ERAD substrates in a soluble state and to help determine the 
fate of misfolded proteins. This work establishes a new role 
for Hsp90 in the extraction of a soluble ERAD substrate from 
the ER. Methods, toxicity assays and dislocation assays per-
formed in this section of our investigation are as described 
above. 
TABLE2 
CTAl exhibits a high affinity interaction with 
Hsp90 and a lower affinity interaction with GRP94. 







7.8 x 10-5 




On rates (ka), off rates (kd), and equilibrium dissociation 
constants (KD) between CTAl and either Hsp90 or GRP94 
were calculated from the data presented in FIG. 8. 





NearUV( 0 C.) 
29.0 
36.0 
Far UV (0 c.) 
31.0 
33.0 
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The transition temperature (midpoint of transition from 
folded to unfolded conformations) for PTS 1 in the absence or 
presence of PBA was calculated from far- and near-UV CD 
data. Near-UV CD monitors changes in tertiary structure; 
far-UV CD monitors changes in secondary structure. Higher 5 
transition temperatures reflect increased protein stability. 
Accordingly, in the drawings and specification there have 
been disclosed typical preferred embodiments of the inven-
tion and although specific terms may have been employed, the 
terms are used in a descriptive sense only and not for purposes 10 
of limitation. The invention has been described in consider-
able detail with specific reference to these illustrated embodi-
ments. It will be apparent, however, that various modifica-
tions and changes can be made within the spirit and scope of 
the invention as described in the foregoing specification and 15 
as defined in the appended claims. 
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to the susceptible host. 
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9. The method of claim 6, wherein the susceptible host 
comprises mammalian cells. 
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10. The method of claim 6, wherein the susceptible host 
comprises human cells. 
11. The method of claim 6, wherein the susceptible host is 
a human. 
12. A method of treating a manmialian cell intoxicated with 
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14. A method of treating a manmialian host intoxicated 
with a bacterial AB-typeADP-ribosylating toxin, the method 
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4-phenylbutyrate (PBA), wherein the toxin comprises chol-
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